HeartSciences (Heart Test Laboratories, Inc.)

United States
Loretto, Tennessee, United States, 76092

Company profile

HeartSciences (Heart Test Laboratories, Inc.) company profile

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Millions of ECGs are performed every week and the Company’s objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.

Business identity

Contact email
[email protected]
Phone number
682-237-7781
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$1M-$10M
Founded
2008-01-01, Year

Headquarters

Postal code
76092
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
8
Total equity funding
$24.3M
Last funding
Post IPO Debt / $1.9M / 2024-09-12
Last equity funding
Series Unknown / $6.5M
Founders
1
Articles
47
Exited on
2022-06-16

Founders and investors

Founders

Drew Diaz